TSRO Share Price

Open 146.39 Change Price %
High 148.50 1 Day -5.68 -3.87
Low 140.50 1 Week -1.10 -0.77
Close 141.03 1 Month -8.08 -5.42
Volume 875614 1 Year 103.82 279.01
52 Week High 192.94
52 Week Low 68.50
TSRO Important Levels
Resistance 2 148.45
Resistance 1 145.39
Pivot 143.34
Support 1 136.67
Support 2 133.61
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
QQQ 138.03 -1.81%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SMSI 1.62 24.62%
CGEI 0.22 22.22%
THTI 0.20 17.65%
MYRX 0.07 16.67%
BDMS 13.50 16.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

TESARO, Inc. (NASDAQ: TSRO)

TSRO Technical Analysis 1.5
As on 27th Jun 2017 TSRO Share Price closed @ 141.03 and we RECOMMEND Buy for LONG-TERM with Stoploss of 134.34 & Sell for SHORT-TERM with Stoploss of 144.87 we also expect STOCK to react on Following IMPORTANT LEVELS.
TSRO Target for June
1st Target up-side 167.36
2nd Target up-side 180.01
3rd Target up-side 192.66
1st Target down-side 131.26
2nd Target down-side 118.61
3rd Target down-side 105.96
TSRO Other Details
Segment EQ
Market Capital 430751968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.tesarobio.com
TSRO Address
TSRO
1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
Phone: 339-970-0900
Interactive Technical Analysis Chart TESARO, Inc. ( TSRO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TESARO, Inc.
TSRO Business Profile
TESARO, Inc. (TESARO) is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�s marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). TSR-011 is an orally available anaplastic lymphoma kinase (ALK), inhibitor (targeted anti-cancer agent) is in preclinical development.